The multiple sclerosis community has reacted enthusiastically to mid-stage data on MediciNova Inc.'s ibudilast which suggests that the drug could be a potential new therapy for people living with progressive forms of the disease for whom there are very limited treatment options.
MediciNova's Ibudilast Shows Potential In Progressive MS
The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.
